Bridgewater, N.J.-based Clinical Genomics is participating in the Fortified Provider Network's and MultiPlan's preferred provider organizations.
Through the agreement, Clinical Genomics' Clovera — a clinically validated blood test designed to detect colorectal cancer recurrence — will be available to the 70 million beneficiaries in these networks.
Clinical Genomics President and CEO Lawrence LaPointe said colorectal cancer patients who underwent treatment will now have access to Clovera.
"Having these established partners in place is critical as we continue to focus on expanding the availability of Clovera nationally. We look forward to productive relationships with both provider groups," he said.